+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Preoperative tumor markers as prognostic factors of colorectal liver metastases



Preoperative tumor markers as prognostic factors of colorectal liver metastases



Hepato-Gastroenterology 56(90): 317-320



Tumor recurrence develops in 45-80% of patients after liver surgery for colorectal liver metastases. To assess the significance of preoperative tumor marker levels for disease free interval (DFI) and patient survival (PS) after liver surgery. Preoperative serum levels of carcinoembryonic antigen--CEA, CA 19-9, CA 72-4, thymidine kinase (TK), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) were evaluated in 173 patients operated on for colorectal liver metastases (CLM). Liver resection was performed on 114 patients and radiofrequency ablation on 59 patients. Preoperative serum levels of TPA (cut off level = 53 IU/L, Hazard ratio = 4.5, Wilcoxon test: p < 0.01, Log-Rank test: p < 0.03) and TPS (cut off level = 81 IU/L, Hazard ratio = 5.1, Wilcoxon test: p < 0.007, Log-Rank test: p < 0.009) were important for PS and DFI after liver resection (TPA: cut off level = 53 IU/L, Hazard ratio = 3.5, Wilcoxon test: n.s., Log-Rank test: n.s.; TPS: cut off level = 81 IU/l, Hazard ratio = 2.6, Wilcoxon test: p < 0.02, Log-Rank: p < 0.06). TPA serum levels were important for PS (Wilcoxon test--p < 0.003, Log-Rank test--p < 0.0002) and DFI after RFA (Wilcoxon test--p< 0.001, Log-Rank Test--p < 0.0001). TPS serum levels also correlated with PS (Wilcoxon test--p < 0.005, Log-Rank test--p < 0.003) and DFI after RFA (Wilcoxon test--p < 0.001, Log-Rank Test--p< 0.0001). TPA and TPS are important predictive markers for PS and DFI after liver resections and radiofrequency ablations for CLM.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055130366

Download citation: RISBibTeXText

PMID: 19579590


Related references

Preoperative Prognostic Factors After Liver Resection for Non-Colorectal, Non-Neuroendocrine Liver Metastases and Validation of the Adam Score in an Asian Population. World Journal of Surgery 42(4): 1073-1084, 2018

The prognostic utility of the "Tumor Burden Score" based on preoperative radiographic features of colorectal liver metastases. Journal of Surgical Oncology 116(4): 515-523, 2017

Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. European Journal of Surgical Oncology 42(9): 1378-1384, 2016

The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. Frontiers in Oncology 8: 181, 2018

FDG PET in preoperative assessment of colorectal liver metastases combining "evidence-based practice" and "technology assessment" methods to develop departmental imaging protocols: should FDG PET be routinely used in the preoperative assessment of patients with colorectal liver metastases?. Academic Radiology 14(4): 389-397, 2007

The prognostic significance of the preoperative full blood count after resection of colorectal liver metastases. Hpb Surgery 2009: 425065, 2009

Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Annals of Surgery 246(5): 806-814, 2007

Impact of preoperative drug therapy on the expression of angiogenesis markers in colorectal liver metastases. Arkhiv Patologii 79(1): 36-42, 2017

Impact of preoperative drug therapy on the expression of apoptosis markers in colorectal liver metastases. Arkhiv Patologii 78(1): 25-31, 2016

Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 119(15): 2778-2788, 2013

Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. Annals of Surgical Oncology 23(11): 3736-3743, 2016

Prognostic markers and staging systems for patients with colorectal liver metastases. Journal of Gastrointestinal Surgery 15(3): 406-409, 2011

Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. European Journal of Cancer 42(12): 1728-1743, 2006

Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases. Journal of Surgical Oncology 114(3): 361-367, 2016

Preoperative Chemotherapy and Risk Factors for Colorectal Liver Metastases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(10): 1286-1288, 2015